Tag: biomarker clinical phase outsourcing services market trends

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Increase In Market Value Is Predicted For The Biomarker Clinical Phase Outsourcing Services Market During The 2026–2030 Period?

The biomarker clinical phase outsourcing services market has undergone substantial expansion in recent years. Its value is anticipated to rise from $11.91 billion in 2025 to $14.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.7%. This past growth can be attributed to several factors, including the increasing complexity of clinical trial designs, a surge in oncology clinical research activity, the progression of biomarker-driven drug development, the broadening of translational research programs, and enhanced collaboration with specialized service providers.

The biomarker clinical phase outsourcing services market size is projected to experience substantial expansion over the coming years. This market is anticipated to reach $30.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. Factors driving this growth during the forecast period include the escalating demand for personalized medicine trials, the increasing integration of AI-driven biomarker analytics, the broadened scope of multi-biomarker clinical studies, rising investments in precision oncology, and heightened regulatory focus on biomarker validation. Key trends anticipated within the forecast period encompass a surge in the outsourcing of biomarker clinical trial activities, the expanding application of predictive and prognostic biomarkers, the increasing incorporation of omics-based biomarker analysis, the progression of companion diagnostics development, and a sharpened emphasis on precision medicine trials.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp

Which Core Factors Are Supporting The Expansion Of The Biomarker Clinical Phase Outsourcing Services Market?

The expansion of clinical trials is projected to fuel the advancement of the biomarker clinical phase outsourcing services market in the future. Clinical trials are investigative studies performed with human subjects to assess the safety and efficacy of new medical treatments, interventions, or diagnostic methodologies. This increase in clinical trials is supported by progress in medical research, a higher occurrence of chronic illnesses, greater financial backing from both public and private sources, and a growing need for innovative treatments and therapies. Outsourcing providers frequently possess specialized expertise and experience in biomarker identification, validation, and analysis. This expertise can enhance the quality and reliability of the biomarker data gathered throughout a trial. For example, in November 2025, the National Library of Medicine, a US-based biomedical library, reported that ClinicalTrials.gov currently lists 558,242 studies with locations in all 51 states and in 224 countries and territories. Consequently, the rise in clinical trials will propel the growth in the biomarker clinical phase outsourcing services market.

How Is The Biomarker Clinical Phase Outsourcing Services Market Examined Through Segment Analysis?

The biomarker clinical phase outsourcing services market covered in this report is segmented –

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types

2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis

3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies, Biotechnology Companies

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers

Which Trends Are Supporting The Evolution Of The Biomarker Clinical Phase Outsourcing Services Market?

Leading companies in biomarker clinical phase outsourcing services are concentrating on improvements involving high-throughput flow cytometry and ELISpot testing to achieve a competitive advantage in the market. These advanced testing methods are employed for biomarker analysis, delivering swift and accurate evaluations of immune responses and cellular markers. For example, in May 2024, KCAS Bio, a U.S.-based bioanalytical Contract Research Organization providing GLP/GCP-compliant biomarker and immune-monitoring services, formed a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO specializing in ELISpot and flow cytometry assays. Through this partnership, KCAS Bio installed harmonized spectral cytometers at Crux Biolabs’ facilities, granting clients access to high-throughput, multiparametric flow cytometry across the U.S., Europe, and Australia. This collaboration reinforces KCAS’s biomarker development and immune-monitoring capabilities by enabling quick and precise assessment of cellular biomarkers in clinical trials, empowering clients to generate high-quality data that supports regulatory submissions and expedites drug development.

Who Are The Companies Shaping The Biomarker Clinical Phase Outsourcing Services Market Landscape?

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.

Access The Complete Biomarker Clinical Phase Outsourcing Services Market Report:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Which Region Accounts For The Highest Share Of The Biomarker Clinical Phase Outsourcing Services Market?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biomarker Clinical Phase Outsourcing Services Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp

Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2026, By The Business Research Company

Biomarker Discovery Outsourcing Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarker-discovery-outsourcing-services-global-market-report

Clinical Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biologics Outsourcing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

“How Much Growth In Market Value Is Expected For The Corporate Wellness Solutions Market Between 2026 And 2030?

The corporate wellness solutions market has seen robust expansion in recent years. Its size is expected to rise from $92.32 billion in 2025 to $100.91 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. The market’s historical growth can be linked to increasing employer healthcare costs, early digital wellness adoption, focus on employee engagement, limited scalability of onsite programs, and rising workplace health risks.

The corporate wellness solutions market is projected to experience substantial expansion in the coming years. It is anticipated to reach $144.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.4%. This growth during the forecast period is fueled by factors such as the rise of hybrid work models, expanded use of digital platforms, an emphasis on outcome-oriented wellness, progress in analytics, and increased employer spending on employee wellbeing initiatives. Significant trends anticipated for this period encompass the increasing uptake of cloud-based wellness platforms, the expansion of virtual wellness and coaching offerings, the incorporation of health analytics and tracking functionalities, the tailoring of employee wellness programs, and the broader availability of remote wellness services.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/corporate-wellness-solutions-global-market-report

What Leading Drivers Are Supporting The Corporate Wellness Solutions Market Expansion?

The increasing emphasis on stress management is anticipated to drive the expansion of the corporate wellness solutions market in the future. Stress management involves learning and applying various cognitive and behavioral methods to handle and deal with stress effectively. Corporate wellness solutions enhance employee productivity, job satisfaction, and general well-being by fostering a work environment that supports mental health and aids in effective stress management. For example, data from Statistics Canada, a Canada-based government agency, indicated that in June 2023, more than 4.1 million individuals, representing 21.2% of the working population, reported elevated or very high levels of work-related stress. Of this group, 7.5% took leave due to stress or mental health concerns in the 12 months before April to June, leading to an average loss of 2.4 days per employed person within this timeframe. Consequently, the growing focus on stress management is a key factor boosting the corporate wellness solutions market.

How Are Different Segments Classified In The Corporate Wellness Solutions Market Segment Analysis?

The corporate wellness solutions market covered in this report is segmented –

1) By Service: Health Risk Assessment, Fitness, Smoking Cessation, Health Screening, Nutrition And Weight Management, Stress Management, Other Services

2) By Product: Cloud-Based, On-Premises

3) By Delivery Model: Onsite, Offsite

4) By End-User: Large Organization, Medium-Sized Organization, Small Organizations

Subsegments:

1) By Health Risk Assessment: Employee Health Risk Surveys, Biometric Screening Assessments, Lifestyle Risk Evaluations, Personalized Risk Reports

2) By Fitness: Onsite Fitness Programs, Virtual Fitness Classes, Strength And Cardio Training Sessions, Group Exercise Initiatives

3) By Smoking Cessation: Counseling And Support Programs, Nicotine Replacement Therapy (NRT), Mobile And App-Based Cessation Tools, Behavioral Therapy Sessions

4) By Health Screening: Blood Pressure And Glucose Testing, Cholesterol And Lipid Panels, Vision And Hearing Assessments, Preventive Health Screenings

5) By Nutrition And Weight Management: Diet Planning Services, Weight Loss Programs, Nutritional Counseling, Healthy Eating Workshops

6) By Stress Management: Mindfulness And Meditation Programs, Yoga And Relaxation Sessions, Employee Assistance Programs (EAP), Stress Reduction Workshops

7) By Other Services: Mental Health Support Services, Ergonomic Assessments, Wellness Challenges And Competitions, Corporate Health Campaigns

What Emerging Trends Are Seen In The Corporate Wellness Solutions Market?

Major companies within the corporate wellness solutions market are developing digital wellness platforms to improve employee well-being by offering a variety of features and tools. A digital wellness platform is a technology-driven solution crafted to promote and assist various dimensions of well-being, including physical, mental, and emotional health, through digital tools and resources. For example, in February 2023, Albertsons Companies Inc., a US-based food and drug retailer, unveiled Sincerely Health. This digital health and wellness platform provides personalized health and pharmacy services, allowing customers to meet their health and wellness aspirations, with reward points redeemable for groceries. Sincerely Health is designed to enable users to make educated decisions regarding food, physical activity, sleep, and mindfulness, thereby elevating their overall well-being. Furthermore, the platform delivers nutrition insights and supports customers in making informed health choices.

Who Are The Companies Driving Activity In The Corporate Wellness Solutions Market?

Major companies operating in the corporate wellness solutions market are UnitedHealth Group, CVS Health Corporation, Elevance Health Inc, Centene Corporation, Well Nation, Cleveland Clinic, Cerner Corporation, Provant Health Solutions Inc., Privia Health Gr, Fitbit Inc., Beacon Health Options, Wellness Corporate Solutions LLC, ComPsych Corporation, Virgin Pulse, Vitality Group, EXOS, Medcan Clinic, Wellsource Inc., Truworth Wellness, Central Corporate Wellness, Marino Wellness, SOL Wellness

Get The Full Corporate Wellness Solutions Market Report:

https://www.thebusinessresearchcompany.com/report/corporate-wellness-solutions-global-market-report

Which Region Is The Top Contributor To The Corporate Wellness Solutions Market By Share?

North America was the largest region in the corporate wellness solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corporate wellness solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Corporate Wellness Solutions Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/corporate-wellness-solutions-global-market-report

Browse Through More Reports Similar to the Global Corporate Wellness Solutions Market 2026, By The Business Research Company

Health And Wellness Market Report 2026

https://www.thebusinessresearchcompany.com/report/health-and-wellness-global-market-report

Corporate Wellness Market Report 2026

https://www.thebusinessresearchcompany.com/report/corporate-wellness-global-market-report

Connected Health And Wellness Solutions Market Report 2026

https://www.thebusinessresearchcompany.com/report/connected-health-and-wellness-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model”

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Biomarker Clinical Phase Outsourcing Services Market In 2026 And 2030?

The market size for biomarker clinical phase outsourcing services has expanded significantly in recent years. It is anticipated to increase from $11.91 billion in 2025 to $14.62 billion in 2026, registering a compound annual growth rate (CAGR) of 22.7%. This historical growth can be linked to the increasing complexity of clinical trial designs, a rise in oncology clinical research activity, the expansion of biomarker-driven drug development, the enlargement of translational research programs, and greater collaboration with specialized service providers.

The biomarker clinical phase outsourcing services market is projected to experience substantial expansion in the coming years, anticipated to reach $30.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. This projected growth during the forecast period is largely driven by factors such as the heightened demand for personalized medicine trials, the increasing integration of AI-driven biomarker analytics, the broadening scope of multi-biomarker clinical studies, expanding investments in precision oncology, and greater regulatory focus on biomarker validation. Key trends anticipated for the forecast period encompass a rise in the outsourcing of biomarker clinical trial activities, increased utilization of predictive and prognostic biomarkers, greater integration of omics-based biomarker analysis, an expansion in companion diagnostics development, and a stronger emphasis on precision medicine trials.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

What Factors Are Contributing To The Growth Of The Biomarker Clinical Phase Outsourcing Services Market?

The increasing number of clinical trials is projected to fuel the expansion of the biomarker clinical phase outsourcing services market in the future. These trials, defined as research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures, are proliferating due to advancements in medical research, a growing incidence of chronic diseases, increased funding from both public and private sectors, and the rising demand for novel treatments and therapies. Outsourcing providers often possess specialized knowledge and proficiency in biomarker discovery, validation, and analysis, which enhances the quality and dependability of the biomarker data gathered throughout the trial process. For instance, in November 2025, the National Library of Medicine, a US-based biomedical library, reported via ClinicalTrials.gov that it currently lists 558,242 studies with locations in all 51 states and in 224 countries and territories. Consequently, the growth in clinical trials is expected to drive the expansion of the biomarker clinical phase outsourcing services market.

How Are Different Segments Classified In The Biomarker Clinical Phase Outsourcing Services Market Segment Analysis?

The biomarker clinical phase outsourcing services market covered in this report is segmented –

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types

2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis

3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies, Biotechnology Companies

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers

What Trends Are Shaping The Future Of The Biomarker Clinical Phase Outsourcing Services Market?

Leading companies in the biomarker clinical phase outsourcing services are concentrating on advancements in high-throughput flow cytometry and ELISpot testing to secure a competitive advantage in the market. These methods are utilized for biomarker analysis, providing quick and accurate assessment of immune responses and cellular markers. For instance, in May 2024, KCAS Bio, a U.S.-based bioanalytical CRO offering GLP/GCP-compliant biomarker and immune-monitoring services, formed a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO specializing in ELISpot and flow cytometry assays. Through this collaboration, KCAS Bio installed harmonized spectral cytometers at Crux Biolabs’ facilities, enabling clients to utilize high-throughput, multiparametric flow cytometry across the U.S., Europe, and Australia. This partnership bolsters KCAS’s biomarker development and immune-monitoring capabilities by delivering rapid, precise evaluation of cellular biomarkers in clinical trials, helping clients generate high-quality data essential for regulatory submissions and accelerating drug development.

Who Are The Companies Driving Activity In The Biomarker Clinical Phase Outsourcing Services Market?

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.

Get The Full Biomarker Clinical Phase Outsourcing Services Market Report:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Which Region Represents The Largest Share Of The Biomarker Clinical Phase Outsourcing Services Market?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biomarker Clinical Phase Outsourcing Services Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2026, By The Business Research Company

Biologics Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Biomarker Discovery Outsourcing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarker-discovery-outsourcing-services-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Biomarker Clinical Phase Outsourcing Services Market In 2026 And 2030?

The market size for biomarker clinical phase outsourcing services has expanded significantly in recent years. It is anticipated to increase from $11.91 billion in 2025 to $14.62 billion in 2026, registering a compound annual growth rate (CAGR) of 22.7%. This historical growth can be linked to the increasing complexity of clinical trial designs, a rise in oncology clinical research activity, the expansion of biomarker-driven drug development, the enlargement of translational research programs, and greater collaboration with specialized service providers.

The biomarker clinical phase outsourcing services market is projected to experience substantial expansion in the coming years, anticipated to reach $30.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. This projected growth during the forecast period is largely driven by factors such as the heightened demand for personalized medicine trials, the increasing integration of AI-driven biomarker analytics, the broadening scope of multi-biomarker clinical studies, expanding investments in precision oncology, and greater regulatory focus on biomarker validation. Key trends anticipated for the forecast period encompass a rise in the outsourcing of biomarker clinical trial activities, increased utilization of predictive and prognostic biomarkers, greater integration of omics-based biomarker analysis, an expansion in companion diagnostics development, and a stronger emphasis on precision medicine trials.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

What Factors Are Contributing To The Growth Of The Biomarker Clinical Phase Outsourcing Services Market?

The increasing number of clinical trials is projected to fuel the expansion of the biomarker clinical phase outsourcing services market in the future. These trials, defined as research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures, are proliferating due to advancements in medical research, a growing incidence of chronic diseases, increased funding from both public and private sectors, and the rising demand for novel treatments and therapies. Outsourcing providers often possess specialized knowledge and proficiency in biomarker discovery, validation, and analysis, which enhances the quality and dependability of the biomarker data gathered throughout the trial process. For instance, in November 2025, the National Library of Medicine, a US-based biomedical library, reported via ClinicalTrials.gov that it currently lists 558,242 studies with locations in all 51 states and in 224 countries and territories. Consequently, the growth in clinical trials is expected to drive the expansion of the biomarker clinical phase outsourcing services market.

How Are Different Segments Classified In The Biomarker Clinical Phase Outsourcing Services Market Segment Analysis?

The biomarker clinical phase outsourcing services market covered in this report is segmented –

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types

2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis

3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies, Biotechnology Companies

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers

What Trends Are Shaping The Future Of The Biomarker Clinical Phase Outsourcing Services Market?

Leading companies in the biomarker clinical phase outsourcing services are concentrating on advancements in high-throughput flow cytometry and ELISpot testing to secure a competitive advantage in the market. These methods are utilized for biomarker analysis, providing quick and accurate assessment of immune responses and cellular markers. For instance, in May 2024, KCAS Bio, a U.S.-based bioanalytical CRO offering GLP/GCP-compliant biomarker and immune-monitoring services, formed a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO specializing in ELISpot and flow cytometry assays. Through this collaboration, KCAS Bio installed harmonized spectral cytometers at Crux Biolabs’ facilities, enabling clients to utilize high-throughput, multiparametric flow cytometry across the U.S., Europe, and Australia. This partnership bolsters KCAS’s biomarker development and immune-monitoring capabilities by delivering rapid, precise evaluation of cellular biomarkers in clinical trials, helping clients generate high-quality data essential for regulatory submissions and accelerating drug development.

Who Are The Companies Driving Activity In The Biomarker Clinical Phase Outsourcing Services Market?

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.

Get The Full Biomarker Clinical Phase Outsourcing Services Market Report:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Which Region Represents The Largest Share Of The Biomarker Clinical Phase Outsourcing Services Market?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biomarker Clinical Phase Outsourcing Services Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2026, By The Business Research Company

Biologics Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Biomarker Discovery Outsourcing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarker-discovery-outsourcing-services-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Biomarker Clinical Phase Outsourcing Services Market Across 2026–2030?

The biomarker clinical phase outsourcing services market size has experienced rapid expansion in recent years. It is projected to increase from $11.91 billion in 2025 to $14.62 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.7%. This historic growth can be linked to several factors, including the increasing complexity of clinical trial designs, a rise in oncology clinical research activity, the advancement of biomarker-driven drug development, the expansion of translational research programs, and enhanced collaboration with specialized service providers.

The biomarker clinical phase outsourcing services market size is projected to experience substantial growth in the coming years. It is expected to expand to $30.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. This anticipated growth during the forecast period is driven by factors such as the increasing demand for personalized medicine trials, the rising adoption of AI-driven biomarker analytics, the expansion of multi-biomarker clinical studies, growing investments in precision oncology, and an increasing regulatory emphasis on biomarker validation. Significant trends in the forecast period include the increasing outsourcing of biomarker clinical trial activities, the rising use of predictive and prognostic biomarkers, the growing integration of omics-based biomarker analysis, the expansion of companion diagnostics development, and an enhanced focus on precision medicine trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp

What Drivers Are Shaping The Future Growth Of The Biomarker Clinical Phase Outsourcing Services Market?

An increase in clinical trials is anticipated to advance the growth of the biomarker clinical phase outsourcing services market in the future. These trials are research endeavors conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The expansion in clinical trials is driven by advancements in medical research, the rising prevalence of chronic diseases, increased funding from both governmental and private sources, and the growing demand for innovative treatments and therapies. Outsourcing providers often possess specialized knowledge and experience in biomarker discovery, validation, and analysis. This expertise can enhance the quality and reliability of the biomarker data collected during the trial. For instance, in November 2025, according to the National Library of Medicine, a US-based biomedical library reported that ClinicalTrials.gov currently lists 558,242 studies with locations in all 51 states and in 224 countries and territories. Therefore, the rise in clinical trials will propel the growth in the biomarker clinical phase outsourcing services market forward.

What Segmentation Levels Are Considered In The Biomarker Clinical Phase Outsourcing Services Market?

The biomarker clinical phase outsourcing services market covered in this report is segmented –

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types

2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis

3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies, Biotechnology Companies

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers

What Key Trends Are Influencing The Development Of The Biomarker Clinical Phase Outsourcing Services Market?

Leading companies in the biomarker clinical phase outsourcing services sector are concentrating on innovations in high-throughput flow cytometry and ELISpot testing to gain a competitive advantage in the market. These methods are utilized for biomarker analysis, enabling swift and accurate assessment of immune responses and cellular markers. For example, in May 2024, KCAS Bio, a U.S.-based bioanalytical Contract Research Organization (CRO) providing GLP/GCP-compliant biomarker and immune-monitoring services, established a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO specializing in ELISpot and flow cytometry assays. Through this partnership, KCAS Bio strategically placed harmonized spectral cytometers at Crux Biolabs’ facilities, thereby allowing clients to access high-throughput, multiparametric flow cytometry capabilities across the U.S., Europe, and Australia. This collaboration significantly enhances KCAS’s biomarker development and immune-monitoring capacities by facilitating rapid, precise assessment of cellular biomarkers in clinical trials, which empowers clients to generate high-quality data supportive of regulatory submissions and accelerates drug development processes.

Which Leading Firms Are Contributing To The Growth Of The Biomarker Clinical Phase Outsourcing Services Market?

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.

Read the full biomarker clinical phase outsourcing services market report here:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Which Geographic Regions Are Influencing Demand In The Biomarker Clinical Phase Outsourcing Services Market?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biomarker Clinical Phase Outsourcing Services Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp

Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2026, By The Business Research Company

Biomarker Discovery Outsourcing Services Global Market Report

https://www.thebusinessresearchcompany.com/report/biomarker-discovery-outsourcing-services-global-market-report

Clinical Biomarkers Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biologics Outsourcing Global Market Report

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model